Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com
Cantor Fitzgerald has increased its price target for Ultragenyx Pharma (NASDAQ: RARE) to $96 from $84, maintaining an Overweight rating. This adjustment follows increased confidence in GTX-102, a treatment for Angelman syndrome, with its probability of success raised to 60%. Despite recent financial misses for Q1 2026, the company reaffirmed its full-year revenue guidance and recently elected three Class I directors.
How this was made
The 30-second read
Why it matters
The analyst upgrade reflects increased confidence in GTX-102's clinical prospects, which could lead to revenue growth and valuation uplift if successful.
Market read
The news is highly relevant for biotech investors, especially those focused on gene therapies and rare disease treatments, with potential sector-wide implications.
What to watch
Potential regulatory hurdles, competition from other therapies, and broader market volatility could impact stock performance despite positive analyst sentiment.
Background
Ultragenyx Pharma is a biotech company focusing on rare and ultra-rare genetic diseases. GTX-102 is a gene therapy candidate for Angelman syndrome, a rare neurogenetic disorder.
Ticker impact
Primary focus of the news, significant impact on stock price due to recent analyst upgrade.
Moderate to strong upward price movement in the short to medium term, contingent on continued positive clinical progress and market reception.
The analyst upgrade and increased confidence in GTX-102's success probability (raised to 60%) suggest improved valuation prospects. The reaffirmed revenue guidance supports a positive outlook, though recent financial misses introduce some caution.
Market effects
Positive impact on biotech and pharmaceutical sectors, especially companies involved in gene therapy and rare disease treatments.
Potential uplift in North American biotech stocks, with possible ripple effects in global markets due to sector influence.
Moderate; primarily affects North American biotech sector, with limited immediate global impact.
Counterpoint
The recent financial misses and the fact that the price target increase is based on a probability estimate (60%) for GTX-102 success suggest caution. If GTX-102 faces setbacks, RARE's stock could decline.
Key entities
- CompanyUltragenyx Pharma
Biotech firm specializing in rare genetic diseases.
- TherapyGTX-102
Gene therapy candidate for Angelman syndrome.
